Pancreatic Cancer Research

ResearcherSamsung Medical CenterActive in the last 2 years

In Woong Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7093-2469; OpenAlex author ID A5036338381, A5108347616. Sources: OpenAlex.

Their work

Papers
42 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
129
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 5 papers · 2021: 5 papers · 2022: 7 papers · 2023: 9 papers · 2024: 1 paper · 2025: 9 papers · 2026: 4 papers

Papers 42

  1. Familial Pancreatic Cancer at a Tertiary Referral Center: Incidence and Clinical Characteristics in Korea. Co-author DOI 10.1002/jhbp.70142↗
  2. Multivisceral resection for pancreatic ductal adenocarcinoma with adjacent organ invasion: a propensity score-matched analysis. Co-author DOI 10.1016/j.gassur.2026.102412↗
  3. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  4. Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… Last author DOI 10.4174/astr.2026.110.2.76↗
  5. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2025.1999↗
  6. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  7. Synthetic data generation method improves risk prediction model for early tumor recurrence after surgery in patients with pancreatic cancer. Co-author DOI 10.1038/s41598-025-15800-4↗
  8. Implications of portal vein/superior mesenteric vein involvement in pancreatic cancer: A comprehensive correlation from preoperative radiological assessment to… Co-author DOI 10.1097/js9.0000000000002307↗
  9. The impact of distress at diagnosis in patients with pancreatic cancer undergoing pancreatectomy. Last author DOI 10.1186/s12885-025-14365-9↗
  10. Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-024-16792-7↗
  11. Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. Co-author DOI 10.1245/s10434-025-18029-7↗
  12. Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study. Co-author DOI 10.4174/astr.2025.108.4.231↗
  13. Predicting prognosis and optimal timing for surgery using CA 19-9 in patients with pancreatic cancer who underwent FOLFIRINOX-based neoadjuvant therapy: a retr… Co-author DOI 10.4174/astr.2025.109.6.348↗
  14. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Last author DOI 10.1016/j.ctro.2024.100732↗
  15. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  16. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  17. Use of individualized 3D-printed models of pancreatic cancer to improve surgeons' anatomic understanding and surgical planning. Co-author DOI 10.1007/s00330-023-09756-0↗
  18. Cryopreserved allografts versus end-to-end anastomosis for the reconstruction of a segment-resected portomesenteric vein during advanced pancreatic cancer surg… Co-author DOI 10.1016/j.asjsur.2023.02.050↗
  19. Prognosis of pancreaticoduodenectomy in octogenarians for pancreatic ductal adenocarcinoma with propensity score matched analysis. Co-author DOI 10.1111/ans.18679↗
  20. Effects of cancer stigma on quality of life of patients with hepatobiliary and pancreatic cancer. Last author DOI 10.14701/ahbps.22-084↗
  21. Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Last author DOI 10.3390/biomedicines11082302↗
  22. 15-Year Experience of Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer-A Korean Nationwide Investigation. Last author DOI 10.3390/cancers15153850↗
  23. Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma. Co-author PMID 37293149↗
  24. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  25. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  26. Utility of Diffusion-Weighted MRI for Detection of Locally Recurrent Pancreatic Cancer After Surgical Resection. Co-author DOI 10.2214/ajr.22.27739↗
  27. Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. Last author DOI 10.3390/biomedicines10061341↗
  28. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194556↗
  29. Pathological Response Predicts Survival after Pancreatectomy following Neoadjuvant FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.3390/cancers15010294↗
  30. Intraoperative Positive Pancreatic Parenchymal Resection Margin: Is It a True Indication of Completion Total Pancreatectomy after Partial Pancreatectomy for Pa… Last author DOI 10.3390/curroncol29080420↗
  31. Appraisal of 5-year recurrence-free survival after surgery in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.815↗
  32. Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion. Co-author DOI 10.1016/j.asjsur.2020.07.021↗
  33. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Co-author DOI 10.1177/17588359211038478↗
  34. Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes. Co-author DOI 10.21873/anticanres.15386↗
  35. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  36. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  37. Clinical outcomes of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma depending on preservation or resection of pylorus. Co-author DOI 10.14701/ahbps.2020.24.3.269↗
  38. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  39. Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer. Co-author DOI 10.23736/s0026-4733.19.07958-6↗
  40. Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors. First author DOI 10.3390/cancers12010137↗
  41. Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection. Co-author DOI 10.1016/j.ijsu.2017.02.007↗
  42. A Case of Leukemoid Reaction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4166/kjg.2015.66.2.116↗

Closest collaborators

The 25 strongest of 129 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Seok Heo · 33 shared papers, 2017–2026 · strength 5.88
  2. Sang Hyun Shin · 27 shared papers, 2020–2026 · strength 5.44
  3. Hongbeom Kim · 18 shared papers, 2020–2026 · strength 3.91
  4. So Jeong Yoon · 16 shared papers, 2021–2026 · strength 3.35
  5. Hochang Chae · 8 shared papers, 2025–2026 · strength 2.16
  6. Hye Jeong Jeong · 8 shared papers, 2022–2025 · strength 1.78
  7. Hyeong Seok Kim · 6 shared papers, 2025 · strength 1.51
  8. Ji Hye Min · 6 shared papers, 2022–2025 · strength 1.20
  9. Joon Oh Park · 8 shared papers, 2020–2025 · strength 1.07
  10. Joo Kyung Park · 6 shared papers, 2020–2025 · strength 0.90
  11. Chang Moo Kang · 5 shared papers, 2020–2026 · strength 0.85
  12. Jong Kyun Lee · 4 shared papers, 2022–2025 · strength 0.70
  13. Kyu Taek Lee · 4 shared papers, 2022–2025 · strength 0.70
  14. Ho Kyoung Hwang · 3 shared papers, 2023–2026 · strength 0.65
  15. Wooil Kwon · 5 shared papers, 2020–2026 · strength 0.61
  16. Jin‐Young Jang · 5 shared papers, 2020–2023 · strength 0.60
  17. Yoo‐Seok Yoon · 4 shared papers, 2021–2026 · strength 0.59
  18. Chang-Sup Lim · 4 shared papers, 2021–2026 · strength 0.56
  19. Hyun Jeong Jeon · 3 shared papers, 2022–2023 · strength 0.55
  20. Kyunga Kim · 3 shared papers, 2022–2025 · strength 0.53
  21. Sung Hyun Kim · 2 shared papers, 2025–2026 · strength 0.53
  22. Seung Soo Hong · 2 shared papers, 2025–2026 · strength 0.53
  23. Hee Chul Park · 3 shared papers, 2022–2025 · strength 0.52
  24. Jeong Il Yu · 3 shared papers, 2022–2025 · strength 0.52
  25. Jung Yong Hong · 3 shared papers, 2021–2025 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.